目的探讨头孢哌酮钠舒巴坦钠的不同给药途径对治疗腹膜透析相关性腹膜炎的临床效果.方法本项研究选择接受腹膜透析相关性腹膜炎治疗的60例患者作为研究对象,将入组患者随机分为两组,即观察组与对照组.观察组患者通过腹膜透析通路给药,将头孢哌酮钠舒巴坦钠1.5 g加入1.5%腹透液2 000 m L中,留腹过夜,疗程为2周,2次/d.对照组患者通过静脉给药,给予0.9%生理盐水100 m L+头孢哌酮钠舒巴坦钠1.5 g静脉滴注,疗程为2周,2次/d.结果观察组有15例(50.0%)患者痊愈,对照组有10例(33.3%)患者痊愈,两组比较差异具有统计学意义.结论在使用头孢哌酮钠舒巴坦钠进行腹膜透析相关性腹膜炎治疗过程中,通过腹膜透析通路给药途径治疗效果理想,值得临床推广使用.
特发性膜性肾病(IMN)的诊断依赖于病史、临床表现和实验室检查,如尿液、血清蛋白电泳等。肾脏组织病理学检查和免疫荧光检测是确诊关键步骤。治疗方面,糖皮质激素是首选,但长期使用带来风险,因此研究着眼于免疫抑制剂和生物制剂。个体化治疗、支持性治疗和新技术(如免疫吸附治疗、基因编辑)是未来发展的方向。多中心研究和精准医学将为治疗带来新思路。The diagnosis of idiopathic membranous nephropathy (IMN) depends on medical history, clinical manifestations, and laboratory tests such as urine and serum protein electrophoresis. Pathological examination of kidney tissue and immunofluorescence testing are key steps for diagnosis. In terms of treatment, glucocorticoids are the preferred choice, but long-term use carries risks, so research focuses on immunosuppressants and biologics. Individualized therapy, supportive therapy, and new technologies such as immunoadsorption therapy and gene editing are the directions for future development. Multi center research and precision medicine will bring new ideas to treatment.
